Paper Details

  1. Home
  2. Paper Details

Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis.

Author: , BärF, BüningC, BüningJ, DietrichN A, FellermannK, HelwigU, KrauseT, KühbacherT, SchmelzR, SchreiberS, StallmachA, TeichN, WalldorfJ

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Vedolizumab may be an option for the treatment of patients with chronic, antibiotic-dependent or refractory pouchitis.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The most common complication after ileal pouch anal anastomosis in up to 50% of patients is an acute pouchitis. The majority of patients respond to antibiotic treatment. However, 10%-15% develops chronic antibiotic-dependent or refractory pouchitis which is usually hard to treat. AIM: T...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/apt.14479

データ提供：米国国立医学図書館（NLM）

Vedolizumab: A Potential Solution for Chronic Pouchitis

Pouchitis, a common complication after ileal pouch anal anastomosis, can be challenging to manage, especially when it becomes chronic and resistant to antibiotics. This study investigates the effectiveness of vedolizumab, a medication targeting gut inflammation, in patients with chronic pouchitis. The study retrospectively analyzed data from 20 patients with chronic, antibiotic-dependent or refractory pouchitis who were treated with vedolizumab. The results demonstrated a significant improvement in pouchitis symptoms, as measured by the Oresland Score and the pouch disease activity index. This indicates that vedolizumab could be a valuable option for patients with chronic pouchitis who have not responded to conventional therapies.

Vedolizumab: A Promising Treatment Option for Chronic Pouchitis

The study found that vedolizumab significantly improved pouchitis symptoms in patients with chronic, antibiotic-dependent or refractory pouchitis. This finding suggests that vedolizumab could be a valuable therapeutic option for patients who have not responded to conventional treatment approaches. The study also highlighted the potential for vedolizumab to reduce the need for antibiotics and other medications.

Vedolizumab: A Targeted Approach to Gut Inflammation

Chronic pouchitis can significantly impact quality of life. Vedolizumab, a medication targeting gut inflammation, offers a targeted approach to managing this condition. This medication could potentially improve symptoms, reduce the need for antibiotics, and enhance overall well-being for patients with chronic pouchitis.

Dr. Camel's Conclusion

Just as a camel can navigate the arid desert landscape, vedolizumab, a targeted medication, can help navigate the challenges of chronic pouchitis. This research suggests that vedolizumab could be a valuable tool for managing this complex and often resistant condition, potentially offering relief for individuals struggling with chronic pouchitis and improving their quality of life.

Date :
  1. Date Completed 2019-03-12
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

29266360

DOI: Digital Object Identifier

10.1111/apt.14479

Related Literature

Article Analysis
・Side Effects of loperamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.